Toshio Shimokawa
Overview
Explore the profile of Toshio Shimokawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
207
Citations
1778
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jinnin M, Shimokawa T, Kishi A, Hayashi N, Nagahama M, Kubo A, et al.
J Dermatol
. 2025 Mar;
PMID: 40040594
The efficacy, safety, and optimal concentration of topical sirolimus gel for treatment of cutaneous lesions of vascular anomalies requires evaluation. This study was a multicenter, double-blind, placebo-controlled, parallel-group, phase II...
2.
Kawada J, Sakai D, Kimura Y, Hirao M, Nishikawa K, Sugimoto N, et al.
Anticancer Res
. 2025 Mar;
45(3):1077-1085.
PMID: 40037863
Background/aim: Irinotecan is a key drug for patients with advanced gastric cancer. We assessed the efficacy and safety of combination chemotherapy with trastuzumab and irinotecan in patients with advanced human...
3.
Shinkai M, Imano M, Yokokawa M, Tanaka R, Matsuyama J, Shimokawa T, et al.
Ann Surg Oncol
. 2025 Feb;
PMID: 39934541
No abstract available.
4.
Ohnishi J, Ishimaru N, Shimokawa T, Kinami S, Nakajima T, Kanzawa Y, et al.
J Eval Clin Pract
. 2025 Feb;
31(1):e70024.
PMID: 39930708
Background: Blood culture is important in the diagnosis of blood infections and the identification of treatment strategies. Increased contamination in blood culture is a reduction in quality of care. This...
5.
Okuda Y, Kuriyama T, Tsukiyama Y, Shimokawa T, Wan K, Kawamata T
Support Care Cancer
. 2025 Jan;
33(2):115.
PMID: 39836290
Purpose: Opioid-induced constipation (OIC) is problematic for patients with cancer receiving opioid therapy. Some guidelines recommend initiating regular laxatives at the same time as opioid analgesics. However, the effectiveness of...
6.
Shinkai M, Imano M, Yokokawa M, Tanaka R, Matsuyama J, Shimokawa T, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2651-2661.
PMID: 39812918
Background: To improve the prognosis of clinically resectable type 4 or large type 3 gastric cancer (GC), we performed a phase I/II study of neoadjuvant-radiotherapy combined with S-1 plus cisplatin....
7.
Sugimoto N, Noura S, Kato T, Yoshioka S, Hata T, Naito A, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796720
Background: FOLFIRI (5-FU + leucovorin + irinotecan) plus ramucirumab is one of the standards in second-line metastatic colorectal cancer (CRC) patients progressing after treatment with oxaliplatin/fluoropyrimidine with bevacizumab, but there...
8.
Sugimoto N, Kawada J, Oka Y, Ueda S, Murakami K, Nishikawa K, et al.
Anticancer Res
. 2024 Dec;
45(1):307-313.
PMID: 39740851
Background/aim: No prospective study has evaluated salvage chemotherapy with capecitabine plus oxaliplatin (XELOX) in patients with gastric cancer who are resistant to or intolerant of cisplatin. Patients And Methods: This...
9.
Yamashita Y, Ashida R, Shimokawa T, Ikeda T, Inatomi O, Ogura T, et al.
Trials
. 2024 Dec;
25(1):852.
PMID: 39732704
Background: Gastrointestinal subepithelial lesions (SELs) range from benign to malignant. Endoscopic ultrasound (EUS)-guided fine-needle biopsy (EUS-FNB) is used widely for pathological diagnosis of SELs. Early diagnosis and treatment are important...
10.
Shinkai M, Imano M, Yokokawa M, Matsuyama J, Kimura Y, Shimokawa T, et al.
Med Oncol
. 2024 Dec;
42(1):31.
PMID: 39699794
Purpose The prognosis for type 4 and large type 3 gastric cancer (GC) is extremely poor, especially in elderly patients (≥ 75 years). To improve the prognosis of these types...